Rights and Permissions
Anirban Basu, Vimalanand S Prabhu, Mary Beth Dorr, Yoav Golan, Erik R Dubberke, Oliver A Cornely, Sebastian M Heimann, Alison Pedley, Ruifeng Xu, Mary E Hanson, Stephen Marcella, Bezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials, Open Forum Infectious Diseases, Volume 5, Issue 11, November 2018, ofy218, https://doi.org/10.1093/ofid/ofy218 © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work
is properly cited. For commercial re-use, please contact email@example.com DOI: 10.1093/ofid/ofy218
Basu, Anirban; Prabhu, Vimalanand S.; Dorr, Mary Beth; Golan, Yoav; Dubberke, Erik R.; Cornely, Oliver A.; Heimann, Sebastian M.; Pedley, Alison; Xu, Ruifeng; Hanson, Mary E.; and Marcella, Stephen, ,"Bezlotoxumab Is associated with a reduction in cumulative inpatient-days: Analysis of the hospitalization data from the MODIFY I and II clinical trials." Open Forum Infectious Diseases.,. . (2018).